David S. Healey

Covid-19 and the virtual generation

Sarah Anderson, Cheryl Bardell, Abigail Doe, E.D. Grady et autres

4 Application of Protein Blotting to the Serodiagnosis of Human Immunodeficiency Virus Infection

William J. Maskill, Colin Silvester, David S. Healey

Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy

Margitta Worm, Hae‐Hyuk Lee, Jörg Kleine‐Tebbe, Roderick P. Hafner et autres

de, gb, fr, ca (code pays fourni par la source)

From Placebo to Panacea Putting Psychiatric Drugs to the Test. Edited by Seymour Fisher and Roger P. Greenberg. J. Wiley and Sons, Chichester, 1997. pp. 404, �39�95.

David S. Healey

gb (code pays fourni par la source)

Multisite Evaluation of Four Anti-HIV-1/HIV-2 Enzyme Immunoassays

Colin Silvester, David S. Healey, Philip Cunningham, Mayra Elizabeth

The performance of four enzyme immunoassays, manufactured by Abbott, Diagnostics Pasteur, Genetic Systems, and Organon Teknika, for the combined detection of anti-human immunodeficiency virus type 1 (HIV-1) and anti-HIV-2, was examined in a multisite evaluation. The collaborative efforts of 7 Australian Red …

au (code pays fourni par la source)

Apparent HIV-1 glycoprotein reactivity on Western blot in uninfected blood donors

David S. Healey, Wayne Bolton

OBJECTIVES: To investigate samples with 'false-positive' reactivity to HIV-1 glycoproteins on Western blot (WB). DESIGN: Samples from 13 blood donors with glycoprotein reactivity were examined for serological evidence of HIV infection and followed-up where possible. METHODS: Samples were tested for anti-HIV-1, HIV-1 …

au (code pays fourni par la source)

An evaluation of two simple synthetic peptide based anti-HIV assays

David S. Healey, Elizabeth M. Dax

au (code pays fourni par la source)

HIV-1 western blot: development and assessment of testing to resolve indeterminate reactivity.

David S. Healey, William J. Maskill, Teresa Howard, V. A. Armstrong et autres

OBJECTIVE: To reduce the number of HIV-1 Western blot (WB)-indeterminates requiring follow-up and the time taken to provide a clear positive or negative result. DESIGN: In the first of two stages, a testing and follow-up strategy was developed to resolve anti-HIV-1 status …

au (code pays fourni par la source)

Low risk of HIV‐1 infection from blood donation: a test‐based estimate

Elizabeth M. Dax, David S. Healey, Nick Crofts

Maroc, au (code pays fourni par la source)

HIV-1 Western blot

David S. Healey, William J. Maskill, Teresa Howard, V. A. Armstrong et autres

Objective To reduce the number of HIV-1 Western blot (WB)-indeterminates requiring follow-up and the time taken to provide a clear positive or negative result. Design In the first of two stages, a testing and follow-up strategy was developed to resolve anti-HIV-1 status …

au (code pays fourni par la source)

Reactivity to non-viral proteins on Western blot mistaken for reactivity to HIV glycoproteins

David S. Healey, Teresa Howard

Detection of anti-HIV immunoglobulin M by particle agglutination following acute HIV infection

David S. Healey, William J. Maskill, Ian D. Gust

In a study of 23 subjects infected with HIV, a modified particle agglutination assay was used to detect anti-HIV-specific immunoglobulin M (IgM). The presence of anti-HIV IgM was demonstrated in every subject, becoming detectable 1-2 weeks after the onset of acute symptoms, …

au (code pays fourni par la source)